What is the main business of Biofar?

The main business activity of Biofar focuses on wholesale of pharmaceutical goods.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on February 6, 2009.

Where is the headquarters located?

The headquarters is located at: Kopernika 38, 90-552 Łódź.

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

In 2025, the company generated total revenue of $12,405, representing an increase of 113.5% compared to 2024.

Is the company profitable?

No, the company recorded a net loss of $99,276 in 2025. For comparison, in 2024 the loss was $48,025, meaning the company increased its loss by 106.3%.

Which cost dominates operating expenses?

The largest operating cost category falls under external services. This category amounted to $53,938 in 2025, representing 51% of all operating expenses.

Biofarsp. k.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2009-02-06

Limited partner contribution

5,000.00 PLN

Activity description

Biofar is a pharmaceutical company founded in 2009 and part of a group of family businesses with 25 years of experience in the medical, pharmaceutical and aesthetic medicine industries. It supplies hospitals and medical facilities across Poland with biological, oncology, cardiology and gastroenterology preparations, as well as antibiotics and antifungals.

Registered address

Kopernika 38, 90-552 Łódź, Poland

Website

biofar.pl

Phone

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 39 days early.

202527/06/2026
202428/06/2025
202328/05/2024
202226/06/2023
202121/06/2022
202030/06/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 12.41kMedianUSD 1.06mAverageUSD 22.40m

Net profit

This companyUSD -99.28kMedianUSD 37.33kAverageUSD 880.24k

Operating costs

This companyUSD 105.54kMedianUSD 922.77kAverageUSD 21.08m

Assets

This companyUSD 167.27kMedianUSD 608.93kAverageUSD 11.85m

Industry

Offer

Biological preparations
Oncological preparations
Cardiological preparations
Antibiotics
Antifungal preparations
Gastroenterological preparations

Partners

Partners
Biofar Sp. z o.o.
Biofar sp. z o.o.
Jakub Konrad Krochmalskiage 50
Roman Paweł Mamrotage 53

Manner of representation

The right to represent the company, make declarations and sign on its behalf is vested in each general partner acting independently.

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2020-04-01.

Bank Gospodarstwa Krajowego
88 1130 1163 0014 7170 2620 0001
Bank Gospodarstwa Krajowego
61 1130 1163 0014 7170 2620 0002

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication date	Event
Jan 11, 2019	Dissolution without liquidation opened

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Pharmbiopolsp. z o.o.	$99,211.10	pharmbiopol.com
Apteczka Pacjentasp. z o.o.	$30,042.28	apteczkapacjenta.pl
Biofertasp. z o.o.	$28,736.12	bioferta.eu
Edge Pharmasp. z o.o.	$19,855.64	edgepharma.eu
Filicosp. z o.o.	$11,710.75	filico.eu
Microbasesp. z o.o.	$5,794.03	microbase.pl
Orfamaksp. z o.o.	$4,869.04	orfamak.eu
BIATsp. z o.o.	$2,327.20	biat.pl

Change history

Date	Event
2019-11-05	Name change (Medica Magnus → Biofar Spółka Z Ograniczoną Odpowiezialnością)
2019-11-05	PKD change (Removed: 200 codes; Added: 9 codes)
2009-02-06	Entered in the register

FAQ

Last updated: 2026-09-30